A new therapeutic paradigm: radioiodine combined with lenvatinib for radioiodine-avid metastatic well-differentiated thyroid cancer
HDRI, with Lenvatinib, was well-tolerated and demonstrated potential benefits in radioiodine-avid metastatic WDTC. Unprecedented fall in thyroglobulin and partial imaging response noted with single therapy cycle. Despite small sample size, preliminary data suggests synergistic treatment effect. Further investigation with a larger cohort is warranted to confirm findings and explore potential response predictors.
Authors
- Amitabh Arya (ORCID: https://orcid.org/0000-0002-8507-4409)
- Sanjay Gambhir (ORCID: https://orcid.org/0000-0001-8764-3890)
- Sukanta Barai (ORCID: https://orcid.org/0000-0003-0641-3693)
- Prabhakar Mishra (ORCID: https://orcid.org/0000-0003-4769-9106)
- Manish Ora (ORCID: https://orcid.org/0000-0002-9748-2215)
- Siddharth Sharma (ORCID: https://orcid.org/0000-0003-0454-6126)
- Prasanta Kumar Pradhan (ORCID: https://orcid.org/0000-0002-1549-0431)
Institutions
- Sanjay Gandhi Post Graduate Institute of Medical Sciences (IN)
- Centre of Biomedical Research (IN)
Publication Details
- Journal
- Nuclear Medicine Communications
- Published
- 2025-04-01
- DOI
- https://doi.org/10.1097/mnm.0000000000001980
- Citations
- 2
- Primary Topic
- Thyroid Cancer Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 2.59